Baxter

View All

Dubai healthcare
Dubai: A leading and exciting pharma hotspot

The dream of the UAE government to place its capital city among the best cities in the world has led to the introduction of ‘Dubai plan 2021’, focused on transforming into a smart city through an investment of more than USD 7 Billion. Dubai’s smart city strategy includes over 100 initiatives, which aims at fosterin...

Find More

Hemophilia A- Market Scenario

Hemophilia is the most common inherited bleeding disorder which leads to spontaneous bleeding as the blood does not clot properly. Hemophilia, characterized by the spontaneous bleeding and swollen joints due to bleeding into the joints, is of several different types- such as Hemophilia A, Hemophilia B, and...

Find More

Payers block EpiPen; Allergan charged; AbbVie’s Humira; Baxter paying $18M

Payers block Kaléo's expensive EpiPen challenger Kaléo reintroduced its Auvi-Q last week at a list price of $4,500 for a two-pack in an effort to capture some market share from Mylan’s EpiPen, which is listed at about $600 for a two-pack. Auvi-Q is set to launch next month. Under Kaléo’s pricing strategy, Auvi-Q wil...

Find More

Delveinsight
Global Hemophilia Market

Get Market Intelligence of Hemophilia Market with DelveInsight The Haemophilia Market is driven by clotting factor concentrates. Besides hemophilia A and B, and those with von Willebrand disease (VWD), is also sometimes treated with clotting factor. Currently about 20,000 people have hemophilia in the US; about ...

Find More